Stocks · News reference
Lakefront Biotherapeutics (NASDAQ:LKFT) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of $(13.52) by 102.14 percent. This is a 120 percent increase over losses of $(1.45) per
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT) received a transparency notification from Bank of America.Pursuant to Belgian transparency legislation1, Lakefront received a transparency notification from
Read original at benzingaMorgan Stanley analyst Judah Frommer maintains Lakefront Biotherapeutics (NASDAQ:LKFT) with a Equal-Weight and lowers the price target from $30 to $26.
Read original at benzingaRBC Capital analyst Brian Abrahams maintains Lakefront Biotherapeutics (NASDAQ:LKFT) with a Sector Perform and lowers the price target from $28 to $26.
Read original at benzinga